Home

duisternis Politiek kijken exenatide bid Voortdurende land bevestigen

Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis - ScienceDirect
Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis - ScienceDirect

Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study - ScienceDirect
Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study - ScienceDirect

Abstract 13242: Risk of Cardiovascular Events in Patients with Type 2 Diabetes Treated With Exenatide BID or Other Glucose-Lowering Therapies: A Retrospective Analysis of the LifeLinkTM Database | Circulation
Abstract 13242: Risk of Cardiovascular Events in Patients with Type 2 Diabetes Treated With Exenatide BID or Other Glucose-Lowering Therapies: A Retrospective Analysis of the LifeLinkTM Database | Circulation

GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond - New Insights 2015. - Abstract - Europe PMC
GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond - New Insights 2015. - Abstract - Europe PMC

Glycaemic control and hypoglycaemia in metformin-treated T2DM patients with exenatide BID vs insulin lispro TID added to titrated insulin glargine QD: the 4B trial - Virtual Meeting | EASD
Glycaemic control and hypoglycaemia in metformin-treated T2DM patients with exenatide BID vs insulin lispro TID added to titrated insulin glargine QD: the 4B trial - Virtual Meeting | EASD

Comparison between twice-daily (BID) exenatide (10 mg) and once-daily... | Download Scientific Diagram
Comparison between twice-daily (BID) exenatide (10 mg) and once-daily... | Download Scientific Diagram

Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin - Endocrine Practice
Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin - Endocrine Practice

Safety and tolerability of exenatide once weekly in patients with type | DMSO
Safety and tolerability of exenatide once weekly in patients with type | DMSO

MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? in: European Journal of Endocrinology Volume 181 Issue 6 (2019)
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? in: European Journal of Endocrinology Volume 181 Issue 6 (2019)

exenatide [TUSOM | Pharmwiki]
exenatide [TUSOM | Pharmwiki]

Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice | International Journal of Obesity
Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice | International Journal of Obesity

The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial - Diabetes Research
The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial - Diabetes Research

PDF] Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA. | Semantic Scholar
PDF] Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA. | Semantic Scholar

Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial - Diabetes Research
Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial - Diabetes Research

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes - Watanabe - 2020 - Journal of Diabetes Investigation - Wiley Online Library
Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes - Watanabe - 2020 - Journal of Diabetes Investigation - Wiley Online Library

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes | Cardiovascular Diabetology | Full Text
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes | Cardiovascular Diabetology | Full Text

Abstract 13242: Risk of Cardiovascular Events in Patients with Type 2 Diabetes Treated With Exenatide BID or Other Glucose-Lowering Therapies: A Retrospective Analysis of the LifeLinkTM Database | Circulation
Abstract 13242: Risk of Cardiovascular Events in Patients with Type 2 Diabetes Treated With Exenatide BID or Other Glucose-Lowering Therapies: A Retrospective Analysis of the LifeLinkTM Database | Circulation

Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis - Diabetes Research and Clinical Practice
Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis - Diabetes Research and Clinical Practice

Estimated average daily usage and cost of exenatide BiD and liraglutide... | Download Table
Estimated average daily usage and cost of exenatide BiD and liraglutide... | Download Table

Compare Diabetes Drugs
Compare Diabetes Drugs

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes | Cardiovascular Diabetology | Full Text
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes | Cardiovascular Diabetology | Full Text

Safety and tolerability of exenatide once weekly in patients with type | DMSO
Safety and tolerability of exenatide once weekly in patients with type | DMSO

Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon | Scientific Reports
Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon | Scientific Reports

Buy Byetta® [Exenatide]
Buy Byetta® [Exenatide]

Efficacy and safety of dulaglutide versus placebo and exenatide in type 2 diabetes (AWARD-1) - Virtual Meeting | EASD
Efficacy and safety of dulaglutide versus placebo and exenatide in type 2 diabetes (AWARD-1) - Virtual Meeting | EASD

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. - Abstract - Europe PMC
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. - Abstract - Europe PMC